ST Pharm
에스티팜 · 237690
Health Care Pharmaceuticals · KOSDAQ
Market cap US$1.9B (₩2.6T)
Overview
ST Pharm makes the active pharmaceutical ingredients used in oligonucleotide therapies, a class of medicines that work by targeting genetic material, and in mRNA-based vaccines and drugs, supplying these materials to pharmaceutical and biotech companies worldwide.
Listed on KOSDAQ, Korea's tech and small-cap board, it also provides contract development and manufacturing services (CDMO) for small-molecule drugs. The company has expanded from small-molecule CDMO into oligonucleotide and mRNA ingredients, and it runs its own drug-discovery pipeline alongside its contract manufacturing business.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$206.5M
- FY2024US$198.4M
- FY2025US$240.3M
Operating profit
- FY2023US$24.3M
- FY2024US$20.1M
- FY2025US$39.8M
Net income
- FY2023US$12.7M
- FY2024US$23.5M
- FY2025US$39.5M
Key ratios (FY2025)
Why it matters
ST Pharm is a member of Dong-A Socio Group, a Korean conglomerate, having been brought into the group over a decade ago.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?